Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,166.3
-55.2 (-1.72%)

 

  • STI Straits Times Index
    3,166.3
    -55.2 (-1.72%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,512.2
    -5.4 (-0.35%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,080.5
    -659.6 (-2.67%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,564.1
    -20.1 (-0.56%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,751.6
    -747.7 (-2.53%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,561.6
    -137.8 (-2.06%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,737.0M
  • Value: 1,744.7M
  • Rise: 72
  • Fall: 305
  • Unch: 381

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
HGH0.021-0.004
Sembcorp Marine0.084-0.001
Medtecs Intl0.400+0.110
Genting Sing0.795-0.035
ThaiBev0.695-0.020
QT Vascular0.006-0.002
Singtel2.440-0.030
Tritech0.022+0.001
Suntec Reit1.550-0.020
Hatten Land0.061-

World Indices

World Indices
Name Last Change
Nasdaq 15,491.7 -353.6
HSI 24,080.5 -659.6
HSCEI 8,576.1 -233.7
Jakarta 6,561.6 -137.8
Nikkei 225 28,751.6 -747.7
SSE Comp 3,564.1 -20.1
Shanghai A 3,735.3 -21.1
Shanghai B 281.0 -1.2
KOSPI 2,936.4 -43.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

NLS PHARMACEUTICS LTD NLS PHARMACEUTICS LTD.
Updated on 26 Nov 2021 (End of trading day)
Last (USD): 1.830 Change: +0.060 High: 1.830 Remarks: -
Change (%): +3.39 Low: 1.710

Company Background

NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company was founded by Ronald Hafner and Alexander Zwyer in June 2015 and is headquartered in Stans, Switzerland.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.23710 Trailing EPS (USD) b -0.51644 NAV (USD) c 0.3521
PE a - Trailing PE d - Price / NAV c 5.1974
Dividend Yield (%) e - Cash In Hand (USD) f 0.5877 Issued & Paid-up Shares g 12,068,300
Piotroski F Score 2 Market Cap (M) 22.085 Free Float (%) 50.0
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i n.m.
Net Earnings Growth (%) j -90.942 Net Debt/Equity k Net Cash
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 28 Sep 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.130
-6.63 %
10 Days --0.290
-13.68 %
20 Days --0.330
-15.28 %
Medium Term Return 3 Months --0.590
-24.38 %
6 Months --1.620
-46.96 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference NLS PHARMACEUTICS LTD NASDAQ 22.085 - - 5.1974 -
Industry Pharmaceuticals: Major NASDAQ 2,183.565 86.513 91.614 2.7892 0.027
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 175,301.248 54.850 119.171 4.4108 -
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 122,056.515 8.695 17.625 1.6276 -
Local Peer ROYALTY PHARMA PLC NASDAQ 25,434.519 26.086 32.491 4.3905 0.458
Local Peer VIATRIS INC NASDAQ 15,419.722 - - 0.7294 -
Local Peer REPLIGEN CORP NASDAQ 15,813.064 263.876 133.018 9.2190 -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 8,180.151 - - 7.1040 -
Local Peer EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS NASDAQ 8,325.054 1,167.815 28.260 7.2363 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 7,834.816 - - - -
Local Peer CUREVAC NV NASDAQ 8,254.105 - - - -
Local Peer HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 6,082.200 - - 6.1762 -
Local Peer I MAB SPON ADS EACH REP 2.3 ORD SHS NASDAQ 4,932.615 72.298 72.298 5.7326 -
Local Peer CEREVEL THERAPEUTICS HLDGS INC NASDAQ 4,732.165 - - 7.5224 -
Other Local Peers ALLAKOS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), OPKO HEALTH INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ERASCA INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), QUANTERIX CORPORATION (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ICOSAVAX INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), KRONOS BIO INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), 2SEVENTY BIO INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), PETIQ INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), VERU INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), ANNEXON INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), XILIO THERAPEUTICS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), BEYONDSPRING INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), PROVENTION BIO INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), PHARVARIS NV (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), TRICIDA INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), EVOLUS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), COMPASS THERAPEUTICS INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), CLENE INC (NASDAQ), 89BIO INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), DURECT CORP (NASDAQ), IMMUNIC INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), ALZAMEND NEURO INC (NASDAQ), NEXIMMUNE INC (NASDAQ), MUSTANG BIO INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), ATHENEX INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), OBSEVA SA (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), JOURNEY MEDICAL CORPORATION (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), NOVAN INC (NASDAQ), ENTERA BIO LTD (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), IMARA INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), GENPREX INC (NASDAQ), GALECTO INC (NASDAQ), MEDIWOUND LTD (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), MANNATECH INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), SYNAPTOGENIX INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), BIOFRONTERA INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), RENOVORX INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ),